Automation, Sensors, and Data Analytics: The Next Phase of Single-Use Bioprocessing

Single-use bioprocessing has already transformed the biopharmaceutical manufacturing landscape by offering flexibility, speed, and reduced contamination risk compared to traditional stainless-steel systems. As demand for biologics, vaccines, biosimilars, and advanced therapies such as cell and gene therapies continues to grow, the industry is now entering a new phase of evolution. This next phase is defined by the integration of automation, advanced sensors, and data analytics into single-use bioprocessing systems—fundamentally changing how biomanufacturing operations are designed, monitored, and optimized.

This technological shift is unfolding alongside strong market expansion. The global single-use bioprocessing market was valued at USD 16.2 billion in 2024 and is anticipated to reach USD 34.6 billion by 2030, growing at an annualized rate of 13.5% during the period 2025–2030. This rapid growth reflects rising adoption across biopharmaceutical manufacturing, particularly for complex biologics and personalized therapies that require flexible and efficient production platforms.

Click here to know more - https://netglu.com/read-blog/25031